 SHELTON, CT ACCESSWIRE June 23, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform the Company, has filed its quarterly report for its third quarter of financial year 2020 with the Securities and Exchange Commission. The Company had requested a COVID-19-related extension to file the quarterly report. The Company reported that it had approximately 6.44 Million M of current assets cash, cash equivalents, and prepaid expenses, and current cash liabilities of approximately 1.14M excluding a recent mortgage described below, as of March 31, 2020, the end of the reporting period. 